TABLE 7.

Thirty-day mortality rates in patients with ESBL-producing K. pneumoniae and E. coli bacteremia according to the appropriateness of empirical antimicrobial therapy^a

Organism	Mortalityb with:		P value
	Appropriate empirical antimicrobial therapyc	Inappropriate empirical antimicrobial therapyd
Overall	9/58 (15.5)	7/37 (18.9)	0.666
K. pneumoniae	7/33 (21.2)	3/14 (21.4)	1.000
E. coli	2/25 (8)	4/23 (17.4)	0.407

^aOf 133 patients with bloodstream infection due to ESBL-EK, 95 patients who had received appropriate antimicrobial agents, such as a carbapenem or ciprofloxacin, as definitive therapy were examined. The remaining 38 patients were excluded because they had received inappropriate definitive antimicrobial therapy.

^bData are number of deaths/number of episodes (percent).

^cThis group included patients who had received antimicrobial agents to which the ESBL-EK isolate was susceptible in vitro as initial empirical antibiotics.

^dThis group included patients who had not received any empirical antimicrobial agents or who had received antimicrobial agents to which the ESBL-EK isolate was not susceptible in vitro as initial empirical antibiotics.